Cargando…

Bacteriostatic and Bactericidal Effect of Tigecycline on Leptospira spp.

Tigecycline is a relatively new antimicrobial, belonging to glycylcyclines with antimicrobial activity against a large spectrum of bacteria. Very few data are available on its effect on Leptospira spp., which consist in a bacteriostatic mechanism. The aim of this investigation was to evaluate the ba...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertelloni, Fabrizio, Cilia, Giovanni, Fratini, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459466/
https://www.ncbi.nlm.nih.gov/pubmed/32751670
http://dx.doi.org/10.3390/antibiotics9080467
_version_ 1783576380869443584
author Bertelloni, Fabrizio
Cilia, Giovanni
Fratini, Filippo
author_facet Bertelloni, Fabrizio
Cilia, Giovanni
Fratini, Filippo
author_sort Bertelloni, Fabrizio
collection PubMed
description Tigecycline is a relatively new antimicrobial, belonging to glycylcyclines with antimicrobial activity against a large spectrum of bacteria. Very few data are available on its effect on Leptospira spp., which consist in a bacteriostatic mechanism. The aim of this investigation was to evaluate the bacteriostatic and bactericidal effect of tigecycline on reference Leptospira strains belonging to 16 serovars. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined through the microdilutions method, and tetracycline was used as the control. Results showed that tigecycline had higher MIC and MBC values than tetracycline. Obtained MIC values were between 4 and 32 µg/mL, while MBC values between 16 and >128 µg/mL. Patoc (MIC: 4 µg/mL; MBC: 16 µg/mL) resulted in the most susceptible serovar, while the most resistant were Bataviae (MIC: 32 µg/mL; MBC: 64 µg/mL), Bratislava (MIC: 8 µg/mL; MBC 128 µg/mL), and Tarassovi (MIC: 8 µg/mL; MBC: >128 µg/mL). This is the first investigation focused on the effect of tigecycline against Leptospira spp. reference strains. Since tigecycline is used as a treatment for bacteremia and urinary tract disease, and these symptoms could be linked to Leptospira infection, the possibility of using this antibiotic as a treatment for leptospirosis should be evaluated. Further studies are needed to explore the possibility to use tigecycline for in vivo application against Leptospira.
format Online
Article
Text
id pubmed-7459466
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74594662020-09-02 Bacteriostatic and Bactericidal Effect of Tigecycline on Leptospira spp. Bertelloni, Fabrizio Cilia, Giovanni Fratini, Filippo Antibiotics (Basel) Communication Tigecycline is a relatively new antimicrobial, belonging to glycylcyclines with antimicrobial activity against a large spectrum of bacteria. Very few data are available on its effect on Leptospira spp., which consist in a bacteriostatic mechanism. The aim of this investigation was to evaluate the bacteriostatic and bactericidal effect of tigecycline on reference Leptospira strains belonging to 16 serovars. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined through the microdilutions method, and tetracycline was used as the control. Results showed that tigecycline had higher MIC and MBC values than tetracycline. Obtained MIC values were between 4 and 32 µg/mL, while MBC values between 16 and >128 µg/mL. Patoc (MIC: 4 µg/mL; MBC: 16 µg/mL) resulted in the most susceptible serovar, while the most resistant were Bataviae (MIC: 32 µg/mL; MBC: 64 µg/mL), Bratislava (MIC: 8 µg/mL; MBC 128 µg/mL), and Tarassovi (MIC: 8 µg/mL; MBC: >128 µg/mL). This is the first investigation focused on the effect of tigecycline against Leptospira spp. reference strains. Since tigecycline is used as a treatment for bacteremia and urinary tract disease, and these symptoms could be linked to Leptospira infection, the possibility of using this antibiotic as a treatment for leptospirosis should be evaluated. Further studies are needed to explore the possibility to use tigecycline for in vivo application against Leptospira. MDPI 2020-07-30 /pmc/articles/PMC7459466/ /pubmed/32751670 http://dx.doi.org/10.3390/antibiotics9080467 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Bertelloni, Fabrizio
Cilia, Giovanni
Fratini, Filippo
Bacteriostatic and Bactericidal Effect of Tigecycline on Leptospira spp.
title Bacteriostatic and Bactericidal Effect of Tigecycline on Leptospira spp.
title_full Bacteriostatic and Bactericidal Effect of Tigecycline on Leptospira spp.
title_fullStr Bacteriostatic and Bactericidal Effect of Tigecycline on Leptospira spp.
title_full_unstemmed Bacteriostatic and Bactericidal Effect of Tigecycline on Leptospira spp.
title_short Bacteriostatic and Bactericidal Effect of Tigecycline on Leptospira spp.
title_sort bacteriostatic and bactericidal effect of tigecycline on leptospira spp.
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459466/
https://www.ncbi.nlm.nih.gov/pubmed/32751670
http://dx.doi.org/10.3390/antibiotics9080467
work_keys_str_mv AT bertellonifabrizio bacteriostaticandbactericidaleffectoftigecyclineonleptospiraspp
AT ciliagiovanni bacteriostaticandbactericidaleffectoftigecyclineonleptospiraspp
AT fratinifilippo bacteriostaticandbactericidaleffectoftigecyclineonleptospiraspp